# Regenex Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regenex

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.regenex.com.cn
- Total disclosed funding: $14M
- Latest round: Series C (Jun 16, 2023)
- Investors on record: 4

## About

Established in 2003 and based in Guangzhou, China, Regenex Corporation operates as a reproductive health drugs developer that provides reproductive health drugs, chronic disease drugs and topical drugs. The company cooperates with Jingdong and Tmall, and establishes Langsheng reproductive health institute. It has many subsidiaries, such as Guangzhou Wanfangjian Medicine Co.,Ltd., Guangzhou Lingdong Marketing Planning Co.,Ltd. and Guangzhou Shiao Trading Co.,Ltd. In 2011, the company established R&D center. In February 2023, Dashen Lin medicine group Limited became the strategic partner of the company. In June 2023, it raised over CNY 100 million in series C funding from Chuangyu Capital, Fortune Capital, GF Xinde Investment and Guangzhou Kechuang Guofa Industry Fund Management.

The company focuses on reproductive health medicine, chronic disease medicine and topical medicine fields. Its products are divided into three series, which include male series, female series and LGBT series, such as red deer® sildenafil 100mg, danmei and hyaluronic acid lotion, etc. Technology platforms include chiral drug synthesis, injectable long-acting liposome targeted drug delivery systems, oral slow and controlled release drug delivery systems, rapid release systems for insoluble drugs and rapid analysis of complex systems.

## Funding rounds

- Series C, Jun 16, 2023, $14M — Fortune Capital, GF Xinde Investment, Chuangyu Capital, Guangzhou Industry Investment Holding Group

## Investors

- Fortune Capital — Series C
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series C
- Chuangyu Capital — Series C
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series C